The Institute of Cancer Research

• Science & Technology

Artificial intelligence reveals prostate cancer is not just one disease

Research published in Cell Genomics today has shown that prostate cancer, which affects one in six men in the UK in their lifetime, includes two different subtypes of the disease, also known as evotypes. Research published in Cell Genomics today has shown that prostate cancer, which affects one in six men in the UK in their lifetime, includes two different subtypes of the disease, also known as evotypes.

29 February 2024

• Science & Technology

How MRI add-ons could accelerate the development of new treatments

New research from the ICR is showing us how additional measurements taken by MRI could speed up the development of new drugs that could make chemotherapies more effective New research from the ICR is showing us how additional measurements taken by MRI could speed up the development of new drugs that could make chemotherapies more effective

9 May 2023

• Science & Technology
• Health & Medicine

Prising open the trap: Getting to grips with targeted cancer drug resistance

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding. Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

10 January 2022

• Science & Technology
• Health & Medicine

Targeted prostate cancer screening: Are we there yet?

Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet? Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet?

20 October 2021

• Science & Technology
• Health & Medicine

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference. Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

19 September 2021